MAHEC at Biltmore

Edward Jauch

Mountain Area Health Education Center

Developmental Disabilities

Depression

Endometriosis

Depressive Disorder

Substance Withdrawal Syndrome

Diabetes Mellitus

Syndrome

Overweight

Type 2 Diabetes Mellitus

Major Depressive Disorder

CT-868

AbbVie

Carmot Therapeutics

Insulet

University of North Carolina (UNC)

University of Vermont

condition

Type 1 Diabetes Mellitus

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

This study will evaluate the changes in glycemic control in overweight and obese adults with Type 1 Diabetes Mellitus after receiving CT-868 for 16 weeks. The effectiveness and safety of CT-868 will be compared to placebo. All participants will continue with their standard diabetes care using either an insulin pump (CSII) or multiple daily injections (MDI). Alongside their designated treatment, participants will receive guidance on managing their diabetes, including monitoring blood glucose levels and diet and exercise recommendations. Treatment assignments, either CT-868 plus insulin or placebo plus insulin will be randomly determined.

A Study of CT-868 in Type 1 Diabetes Mellitus

Mountain Area Health Education Center | MAHEC at Biltmore

Site insights

Contact this site

Active trials

A Study of CT-868 in Type 1 Diabetes Mellitus

Trial sponsors